About us

Dianosic designs transformative intranasal solutions changing physicians experience and supporting a rapid return of patients to daily life activities.

Our history

2024

Dianosic poursuit son plan préclinique comme prévu et confirme ses bons résultats initiaux pour le programme DIA01-R.
Un nombre croissant de centres cliniques participent à l’étude observationnelle CAVI-T. 
Les premières études de formulation dans les domaines thérapeutiques du système nerveux central (SNC) (schizophrénie, Parkinson) ont été initiées.

2023

Dianosic lève 4,7 millions d’euros pour préparer un essai clinique sur la rhinite chronique.
Lancement du nouveau ballon CAVI-T doté d’une fonction anti-migration.
Résultats précliniques in vivo prometteurs pour le DIA01-R.
Dianosic ajoute le système nerveux central comme nouveau secteur d’activité et renforce sa plateforme DIAXX.

2022

Dianosic figure parmi les 10 meilleures startups européennes du secteur des technologies médicales.
Conception d’un prototype entièrement fonctionnel de la solution DIAXX pour la rhinite allergique chronique (DIA01-R)

2021

Dianosic reçoit le prix « favori du public » du SNITEM.
Lancement réussi de CAVI-T en Europe après la pandémie de COVID.
Lancement d’outils de formation numérique pour CAVI-T.

2020

Dianosic clôture un premier tour de financement de 1,5 million d’euros.
Publication des premiers résultats cliniques pour CAVI-T.
Marquage CE de CAVI-T et certification ISO 13485.

2019

Dianosic remporte le prestigieux concours d’innovation I-Lab 2019.

2018

Dianosic déménage à Strasbourg.

2017

Développement du ballonnet intranasal asymétrique CAVI-T, une solution minimalement invasive pour améliorer le traitement des épistaxis.
Le programme de développement de l’échafaudage intranasal résorbable actif (DIAXX) débute dans le traitement de la rhinite et de la sinusite.

Origine

Marc Augustin (Président), Philippe Bastide (PDG) et le Pr Christian Debry (chirurgien ORL) créent Dianosic à Paris pour répondre aux besoins non satisfaits en otorhinolaryngologie (ORL) / maladies respiratoires, notamment la rhinite allergique chronique, la rhinosinusite chronique et l’épistaxis.

Our mission and ambitions

Dianosic's Commitment to Enhancing respiratory care

Les affections ORL (oto-rhino-laryngologie) sont la principale cause de consultation médicale. Des améliorations significatives sont possibles pour répondre aux besoins cliniques non satisfaits. Dianosic collabore avec les professionnels de santé afin de proposer des solutions ORL de pointe qui transformeront la vie des patients souffrant de rhinite chronique, de rhinosinusite chronique et d’épistaxis. L’entreprise s’engage à :

Optimiser la qualité de vie des patients, en favorisant un retour rapide aux activités quotidiennes.

Optimiser l’efficacité et la sécurité grâce à une administration ciblée de médicaments à faible dose.

Tirez parti de notre plateforme d’administration intranasale de médicaments pour traiter les maladies du système nerveux central.

Réduire la durée et la fréquence des hospitalisations.

Transformative intranasal solutions Transformative intranasal solutions

Dianosic's future : A paradigm shift with transformative innovations

Discover our programs: DIA01-R, DIA02-S and more

Dianosic développe une plateforme d’implants intranasaux résorbables actifs (DIAXX) visant à administrer une dose réduite et ciblée de médicament dans la cavité nasale grâce à une solution simple et rapide à insérer. DIAXX offre un traitement à libération prolongée, révolutionnant la prise en charge des maladies chroniques telles que la rhinite et la rhinosinusite. La technologie innovante de la plateforme DIAXX est hautement adaptable et prometteuse dans le domaine du système nerveux central, exploitant le concept « du nez au cerveau » dans la schizophrénie, la maladie de Parkinson, etc.

Our programs

Our team

Qualified team with complementary profiles

Marc Augustin Chairman / Founder

Seasoned entrepreneur
>20 years of experience in Finance and International Development (Stellantis, IBM)
Member of the executive committee of the health insurancel company UNEO
Merger Acquisition / fundraising advisor (ACM partners)
Linkedin account: https://bit.ly/3EvE9u1

Philippe Bastide CEO/ Founder

> 20 years of experience in Medtech and Pharma (Pfizer, Johnson & Johnson, Livanova)
Business Unit Lead at Acclarent (ENT Division of Johnson & Johnson)
Expertise in Market Access (pricing & reimbursement), Business Development and Professional Education
Linkedin account: https://bit.ly/3sRamJv

Emilie Fournier, PhD CSO - Chief Scientific Officer

10 years' experience in medical devices and pharmaceuticals (Roche)
Expertise in quality management & regulatory affairs
Doctorate in Biology from the University of Strasbourg (CIFRE SANOFI)
Linkedin account: https://bit.ly/44RT6l2

Eric Le Goff CMC Director

14 years of experience in pharmaceutical development, generics, orphan drugs and combination products
CMC Regulatory Project Management invariuous companies (INNOTHERA, NOVARTIS, OT4B )
Expertise in product development and analytical chemistry
Linkedin account: https://bit.ly/44GfrSh

Khadija Elhabazi, PhD Quality Manager, Clinical Operations Engineer

Quality Manager, Clinical Operations Engineer
10 years' experience in research projects (University of Strasbourg)
Expertise in in vivo studies
PhD in Pharmacology + Diploma in Clinical Research
Linkedin account: https://bit.ly/3sQRomk

Victor Moreau R&D Engineer

Healthcare engineer (Master's degree in healthcare engineering, medical devices option, Montpellier, DEDIENNE SANTÉ)
Expertise in medical device (or healthcare product) design
Specialized in biodegradable polymers and active ingredient release
Linkedin account: https://bit.ly/3LfIgOD

Pedro Costa Campos COO - Chief Operating Officer

Over 20 years' career in the healthcare industry
Solid experience in general management, operational strategy, business development, marketing and sales management at international level, across regions (Johnson & Johnson).
Linkedin account: https://bit.ly/3EvE9u1

Jean-Charles Vignole Sales

Student at ESSCA business school, Master international Business
Professional experience in the Medtech world (Johnson & Johnson)
Linkedin account: https://bit.ly/3ZgllbS

Christophe Kica Finance & Accounting

>20 years experience as chartered accountant, statutory auditor and Financial lead in Medium Caps and startups (Cléry, CTG Group, TheUpScalers).
Linkedin account:
https://www.linkedin.com/in/christophe-kica-50705218/

Pr. Christian Debry ENT surgeon / Founder

ENT Surgeon, University Hospital of Strasbourg, France
Rhinology and skull base surgery expert
Co-Director of the INSERM 1121 Research Unit (“Bioengineering and biomaterial)
Co-Director of the lab for skull base surgery (IRCAD)
Board member of the French ENT Society, French College of ENT and Head & Neck Surgery and the French Association for Pediatric ENT
Founder of Protip Médical (World first implantation of an artificial larynx, 2012)
Linkedin account: https://bit.ly/3P8tcn5

Pr. Howard Levine ENT surgeon

ENT surgeon (USA)
Founding Director of the Cleveland Nasal-Sinus & Sleep Center
Past President of the American Rhinologic Society
Former Vice President of Medical Affairs at Acclarent (J&J)
Featured in the prestigious “Best Doctors in America” and “America’s Top Doctors” lists
Investigator, lecturer and co-author of ENT reference articles

Pr. Wytske Fokkens ENT surgeon

ENT surgeon at Amsterdam University Medical Centres
World renowned specialist in the field of sinus and skull base surgery
Member of the key international Scientific Societies (ERS, EPOS, ARIA, GA2LEN)
Author of more than 500 scientific articles

Pr. Sébastien Froelich Neurosurgeon

Neurosurgeon, Lariboisière Hospital, APHP (Paris)
Neurosurgeon, Lariboisière Hospital, APHP (Paris)
President of the « Skull base » Committee of the Worldwide Federation of Neurosurgery (WFNS)
Executive member of the European Skull Base Society (ESBS)

Dr. Zara Patel Associate ENT Surgeon

Director of Endoscopic Skull Base Surgery (Stanford School of Medicine)
Associate Professor of Otolaryngology – Head and Neck Surgery (Stanford School of Medicine)
Expert in advanced endoscopic sinus and skull base surgery
Member of the Board of Directors (American Rhinologic Society)
Author of ENT reference articles

Pr. Claire Hopkins ENT surgeon

Consultant ENT Surgeon at Guy’s and St Thomas’ Hospital (London)
World renowned specialist focusing on rhinology and anterior skull base surgery
Chair of the UK Rhinosinusitis Commissioning Guidance Group and the Treasurer for the European Rhinologic Society
Claire has published over 150 papers in medical journals and 20 book chapters

Pr. André Coste ENT surgeon

ENT surgeon (CHI Créteil, France)
Specialized in rhinology and skull base surgery
Reviewer in key ENT Journals (B-ENT, Am J Rhinol, Rhinology, Eur Ann of Otolaryngology, Intensive Care Medicine)
Permanent member of the French Rhinology Association (AFR)
Pr. Coste does not receive any financial compensation for his work as scientific advisor

Pr. Olivier Malard ENT surgeon

ENT surgeon (University hospital of Nantes, France)
Expert in rhinology, head and neck surgery
Member of Inserm Research Unit 1229 (Regenerative Medicine and Skeleton (RMeS))
Member of the French Society of Rhinology and Head and Neck Oncology
Pr. Malard does not receive any financial compensation for his work as scientific advisor

Pr. Pablo Stolovitzky ENT Surgeon

Adjunct Associate Professor, Dept. of Otolaryngology, Emory University
CEO, ENT of Georgia North
General Secretary, Pan-American ORL Association
Past Director, AAO-HNS Board of Directors
International Steering Committee, AAO-HNS
President of the 2022 Pan-American Congress of Otolaryngology
Investigator and author of Otolaryngology reference articles

Pr. Eric Vicaut Health Technology Assessment expert

HTA expert, Statistician and clinical trials methodologist (Paris, Fernand Widal, APHP)
Former member of Marketing Authorization Commission and Medical Devices Commission (CNEDIMTS)
Founder of the Medical Devices Evaluation Center (CEDM)
Member of the Galien Awards jury
Pr. Vicaut does not receive any financial compensation for his work as scientific advisor

Philippe Bastide CEO/ Founder

> 20 years of experience in Medtech and Pharma (Pfizer, Johnson & Johnson, Livanova)
Business Unit Lead at Acclarent (ENT Division of Johnson & Johnson)
Expertise in Market Access (pricing & reimbursement), Business Development and Professional Education
Linkedin account: https://bit.ly/3sRamJv

Marc Augustin Chairman / Founder

Seasoned entrepreneur
>20 years of experience in Finance and International Development (Stellantis, IBM)
Member of the executive committee of the health insurancel company UNEO
Merger Acquisition / fundraising advisor (ACM partners)
Linkedin account: https://bit.ly/3EvE9u1

Alex Theodorakis President Aptar Pharma Prescription at Aptar

Alex Theodorakis is President, Aptar Pharma Prescription, he oversees global prescription pharmaceutical activities ($800M), including the Congers, Le Vaudreuil, Mumbai, and Suzhou sites. With over 25 years at Aptar, he began his career in technical support at BLM Associates (later Valois of America, now Aptar).

He subsequently held roles in sales and production across North America, worked in France at the Le Vaudreuil site, and later managed pharmaceutical and commercial operations in the United States before being appointed to his current position in 2017.
Linkedin account:
https://www.linkedin.com/in/alex-theodorakis-b07b7837/

Jérémy Paulen Director Business Development Allergy at Aptar

Jérémy Paulen is Director of Business Development for Allergy & White Spaces at Aptar Pharma. He specializes in innovation, strategic partnerships, and nasal drug-delivery technologies.

With over a decade of experience across pharma, medical devices, and consumer health, he focuses on translating advanced drug-delivery platforms into patient-centric and value-creating solutions.
Linkedin account:
https://www.linkedin.com/in/jeremypaulen/

Jean-Francois RAX Managing Partner – Head of Seed Funding at Capital Grand Est

Jean-François Rax is Partner and Head of Seed Funding, specialized in life sciences. He joined Capital Grand Est in 2014 as Life Sciences Investment Director for the seed fund Cap Innov’Est and has served as a member of the Managing Board since 2020, overseeing the seed investment department (€87M under management).

Previously, he was a collaborator at Inserm Transfert Initiative, a French seed fund dedicated to life sciences and human health.
Linkedin account:
https://www.linkedin.com/in/jean-francois-rax-0946512/

Alexandre Koressios Directeur d’Investissement at Finovam Gestion

Alexandre Koressios is an investment professional and venture capital executive. He is a Member of the Management Board at Finovam Gestion, a venture capital firm specialized in early-stage technology investments in French regions, where he leads the Grand Est office.

He began his career in audit at Deloitte before supporting entrepreneurs at Réseau Entreprendre Paris. He later joined Starquest Capital as Investment Director and participated in around thirty technology startup closings. Alexandre has invested in digital and healthcare companies and actively supports his portfolio through board participation and strategic guidance.
Linkedin account:
https://www.linkedin.com/in/alexandrekoressios/

Séverine Lacourt Global Asset Strategy Lead, Telitacicept at Vor Bio

Séverine is Head of Global Asset Strategy for telitacicept at Vor Bio. Previously, she spent over 15 years at Bristol Myers Squibb (BMS), where she held several senior commercial roles globally in hematology, biomarkers, COVID-19 monoclonal antibodies, and Zeposia, and served as Chief of Staff to CEO Giovanni Caforio.

Her international experience has led her to leadership positions in France, China, and the United States, encompassing commercial excellence, portfolio strategy, and the management of international programs. She began her career at the Boston Consulting Group before holding senior commercial roles in the pharmaceutical industry (GSK, Sanofi, J&J). She is a graduate of HEC Paris and holds an MBA from INSEAD.
Linkedin account:
https://www.linkedin.com/in/severine-lacourt-865763b/

Eric Brandt Investment Manager at Noshaq

Linkedin account:
https://www.linkedin.com/in/eric-brandt-6529613/

Clémentine Lombaert Analyste at Capital Grand Est

Clémentine Lombaert is an Analyst at Capital Grand Est, where she has been working since 2022 on seed-stage investments through the Cap Innov’Est fund.

She contributes to opportunity assessment, due diligence, and the strategic monitoring of portfolio companies. She holds a general engineering degree with a specialization in life sciences, completed following a final-year project in private equity.
Linkedin account:
https://www.linkedin.com/in/cl%C3%A9mentine-lombaert-/

Our partners

We built a solid network of partners to support company funding and growth.

Nous sommes soutenus par des Business Angels, une plateforme de financement participatif de premier plan (Wiseed), la Fondation Force, BPI, Banque Populaire et Caisse d’Épargne Grand Est. Depuis sa création, le soutien de la Région Grand Est, de Quest for Health, de Biovalley France, de Conectus et d’Eurométropole a été d’une importance capitale.

Pour en savoir plus sur nos projets en cours, notre stratégie à long terme et nos partenaires, veuillez consulter notre page « Actualités et partenaires ». Rejoignez-nous et participez à l’aventure Dianosic !

News & partners